Consider Nuances of Esketamine and Ketamine for Depression

June 2025

We’re getting questions about the role of Rx nasal esketamine (Spravato) or IV ketamine for treatment-resistant depression.

Esketamine nasal spray was first approved for use in COMBINATION with an oral antidepressant.   Now, it can also be used as monotherapy.

Evidence suggests that esketamine nasal spray alone statistically improves depression symptom scores when compared to placebo after 4 weeks.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote